Frazier Life Sciences Management, L.P. Portfolio

Auto-discovered 13F filer (Top-2000 by latest reported value).

SEC 13F CIK: 0001892134

What is a 13F filing? Who files one and when · What 13F filings can't tell you

MidFocusedHealth TiltHigh Turnover how tags are computed

Q2 2025 · 49 positions · Total reported value $2.50B · Top-10 concentration 67.8% · Updated 2026-10-18

Last updated: 2026-10-18 · Source: SEC EDGAR Form 13F-HR

Turnover: 22.7% · 6 new · 1 cut · 3 exited

Active Share (vs S&P 500): 100.0% · vs QQQ: 100.0% — share of the book that differs from index weights (higher = more active) · ranking

Est. Qtr Return (Q1 2026 → Q2 2026): +20.6% · vs SPY +5.8% · Prev Value $3.89B — last quarter positions weighted by this quarter price moves · ranking

In its Q2 2025 13F filing, Frazier Life Sciences Management, L.P. disclosed 49 equity positions with a combined reported value of $2.50B. The filing implies a focused portfolio: its ten largest positions account for 67.8% of reported value. HoldingsHub classifies the profile as Mid / Focused / Health Tilt / High Turnover.

The largest disclosed positions as of Q2 2025 were MIRM ($345.80M), VRNA ($320.05M), NAMS ($300.75M). By sector, the heaviest allocations are Health Care 82.3%, Materials 0.2%. Versus the prior quarter, allocation shifted toward Other (+0.9pp) and away from Health Care (-0.8pp).

Versus the prior quarter, Frazier Life Sciences Management, L.P. opened 6 new positions, trimmed 1 and fully exited 3, a turnover rate of 22.7% of positions. The portfolio's overlap with the prior quarter was 75% of names.

The largest new positions opened in Q2 2025 were AURA ($31.93M), EOLS ($22.43M), AKRO ($19.57M).

Of the 3 positions fully exited versus the prior quarter, the largest were RYTM ($35.95M), SLNO ($35.66M), MRUS ($15.70M).

Figures come from the fund's SEC Form 13F filing. 13F reports are filed within 45 days of quarter end and cover long positions of $100,000 or more; they exclude short positions and non-13F asset classes, so treat this page as a quarter-end snapshot rather than the fund's live book.

New Positions (Q2 2025)

  • AURA AURA BIOSCIENCES INC · $31.93M
  • EOLS EVOLUS INC COM · $22.43M
  • AKRO AKERO THERAPEUTICS INC · $19.57M
  • CYTK CYTOKINETICS INC · $18.33M
  • JBIO JADE BIOSCIENCES INC · $17.70M
  • TVTX TRAVERE THERAPEUTICS INC · $14.83M
  • VALN VALNEVA SE · $8.24M
  • CBIO CRESCENT BIOPHARMA INC. · $7.32M

Fully Exited (vs previous quarter)

  • RYTM RHYTHM PHARMACEUTICALS INC · prev qtr: $35.95M
  • SLNO SOLENO THERAPEUTICS INC · prev qtr: $35.66M
  • MRUS MERUS N V · prev qtr: $15.70M
  • ACAD ACADIA PHARMACEUTICALS INC · prev qtr: $7.81M · history
  • RCKT ROCKET PHARMACEUTICALS INC COM · prev qtr: $7.20M
  • IMTX IMMATICS N.V · prev qtr: $5.63M

Insider Transactions (Form 4)

Latest Frazier Life Sciences Management, L.P. buys and sells reported on SEC Form 4 — filed within two business days when the fund's ownership in a stock crosses 10%.

No Form 4 filings for this fund yet — when its ownership in a stock crosses 10%, buys and sells are filed here within two business days.

Fund Profile

Frazier Life Sciences Management, L.P. is an SEC-registered 13F filer. As of Q2 2026 it reported 41 US equity positions with a combined value of $4.59B. HoldingsHub carries 12 quarters of its filings (Q3 2023–Q2 2026).

Portfolio Structure

  • 41 positions · $4.59B reported value (Q2 2026)
  • Top 10 holdings = 73.6% of reported value
  • Largest position: MIRM (MIRUM PHARMACEUTICALS INC) at 19.6%
  • Average position size: $112.00M

Sector Tilt

  • Health Care 99.8%
  • Materials 0.2%
  • (classified holdings cover 100% of value)

Quarterly Activity

  • Q2 2026: 6 new, 8 added, 1 reduced, 3 exited
  • 26 positions unchanged

Generated from the firm's public SEC Form 13F and ADV filings. It states what the firm has reported — not an evaluation of its strategy, and not investment advice.

Sector Allocation

Health Care 82.3%
Materials 0.2%
Other 17.5%
Sort by: Value Shares Weight Sector Change · CSV
# Shares Value Weight Allocation Change
1 6.80M $345.80M 13.83%
13.83%
Hold
2 3.38M $320.05M 12.80%
12.80%
Reduce
3 16.61M $300.75M 12.03%
12.03%
Add
4 3.80M $164.10M 6.56%
6.56%
Hold
5 9.87M $138.44M 5.54%
5.54%
Add
6 12.47M $119.55M 4.78%
4.78%
Add
7 688.46K $94.64M 3.78%
3.78%
Hold
8 1.65M $87.64M 3.50%
3.50%
Reduce
9 5.99M $68.29M 2.73%
2.73%
Hold
10 1.40M $56.61M 2.26%
2.26%
Hold
11 10.26M $56.12M 2.24%
2.24%
Hold
12 4.57M $56.04M 2.24%
2.24%
Add
13 4.89M $55.26M 2.21%
2.21%
Hold
14 1.31M $45.75M 1.83%
1.83%
Add
15 1.28M $42.56M 1.70%
1.70%
Add
16 997.46K $36.70M 1.47%
1.47%
Hold
17 983.72K $35.77M 1.43%
1.43%
Add
18 5.10M $31.93M 1.28%
1.28%
New
19 22.73M $28.87M 1.15%
1.15%
Add
20 1.00M $28.63M 1.15%
1.15%
Add
21 11.46M $26.13M 1.04%
1.04%
Hold
22 9.44M $25.58M 1.02%
1.02%
Add
23 133.33K $23.01M 0.92%
0.92%
Hold
24 2.44M $22.43M 0.90%
0.90%
New
25 10.62M $21.13M 0.84%
0.84%
Hold
26 770.00K $20.02M 0.80%
0.80%
Hold
27 366.78K $19.57M 0.78%
0.78%
New
28 554.73K $18.33M 0.73%
0.73%
New
29 4.42M $17.79M 0.71%
0.71%
Add
30 625.00K $17.75M 0.71%
0.71%
Add
31 1.77M $17.70M 0.71%
0.71%
New
32 722.40K $16.28M 0.65%
0.65%
Add
33 474.40K $15.42M 0.62%
0.62%
Reduce
34 1.00M $14.83M 0.59%
0.59%
New
35 1.51M $14.34M 0.57%
0.57%
Add
36 1.73M $12.45M 0.50%
0.50%
Add
37 384.78K $12.07M 0.48%
0.48%
Add
38 1.07M $10.81M 0.43%
0.43%
Reduce
39 4.62M $10.54M 0.42%
0.42%
Hold
40 1.46M $8.24M 0.33%
0.33%
New
41 453.69K $7.32M 0.29%
0.29%
New
42 1.95M $6.58M 0.26%
0.26%
Hold
43 583.33K $6.54M 0.26%
0.26%
Hold
44 970.13K $5.63M 0.23%
0.23%
Reduce
45 3.87M $4.37M 0.17%
0.17%
Hold
46 500.33K $4.00M 0.16%
0.16%
Hold
47 3.18M $3.84M 0.15%
0.15%
Hold
48 1.07M $2.30M 0.09%
0.09%
Hold
49 5.99M $2.20M 0.09%
0.09%
Hold

FAQ

What did Frazier Life Sciences Management, L.P. buy in 2025-Q2?

In its 2025-Q2 13F filing, Frazier Life Sciences Management, L.P. reported 49 equity positions worth $2.50B in aggregate; its largest disclosed positions were MIRM ($345.80M), VRNA ($320.05M), NAMS ($300.75M).

How large is Frazier Life Sciences Management, L.P.'s portfolio?

Frazier Life Sciences Management, L.P. reported $2.50B of long equity holdings across 49 positions as of 2025-Q2. Top-10 holdings account for 67.8% of reported value.

What is Frazier Life Sciences Management, L.P.'s investment style?

HoldingsHub classifies the portfolio as Mid / Focused / Health Tilt / High Turnover, computed from size, concentration, sector tilt and turnover.

Where does this data come from?

All figures are computed from the fund's SEC Form 13F quarterly filing, which must be filed within 45 days of quarter end for long positions of $100,000 or more.

Embed this fund on your site

Copy the snippet below to show this fund's live top holdings on your blog or forum — free, auto-updating, links back to HoldingsHub.

<iframe src="https://holdingshub.top/funds/frazier-life-sciences-management/widget" width="100%" height="520" frameborder="0" loading="lazy" title="HoldingsHub fund holdings"></iframe>

Preview the embeddable widget →